Imperial College London
Dr David Goldmeier

DrDavidGoldmeier

Faculty of Medicine, Department of Infectious Disease

Honorary Senior Lecturer
 
 
 
//

Contact

 

d.goldmeier

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Thurston:2022:10.1001/jamanetworkopen.2022.36131,
author = {Thurston, L and Hunjan, T and Ertl, N and Wall, M and Mills, E and Suladze, S and Patel, B and Alexander, E and Muzi, B and Bassett, P and Rabiner, E and Bech, P and Goldmeier, D and Abbara, A and Comninos, A and Dhillo, W},
doi = {10.1001/jamanetworkopen.2022.36131},
journal = {Jama Network Open},
pages = {1--14},
title = {Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial},
url = {http://dx.doi.org/10.1001/jamanetworkopen.2022.36131},
volume = {5},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Importance: The absence or deficiency of sexual desire leading to distress or interpersonal difficultydefines ‘hypoactive sexual desire disorder’ (HSDD). Despite being the most common female sexualhealth complaint worldwide, current treatment options for HSDD are limited in their safety andeffectiveness. The hormone kisspeptin is a key endogenous activator of the reproductive hormonalaxis with additional emerging roles in sexual and emotional behavior, however, its effects in womenwith HSDD are unknown.Objective: To test the hypothesis that kisspeptin enhances sexual and attraction brain processing inwomen with HSDD.Design: A randomized, double-blind, two-way crossover, placebo-controlled clinical trial. Functionalneuroimaging, psychometric and hormonal analyses were employed to investigate the effects ofkisspeptin administration on brain processing, in response to erotic stimuli (erotic videos) and facialattraction (face images of varying attractiveness).Setting: The trial was conducted in a university research setting from October 2020 to April 2021. Datawere analyzed from May to December 2021.Participants: 32 premenopausal women with HSDD for at least 6 months’ duration.Interventions: 75-minute intravenous infusion of kisspeptin-54 (1 nmol/kg/h) vs equivalent-rateplacebo infusion.Main Outcome and Measures: Blood oxygen level–dependent responses across the whole brain andregions of interest during kisspeptin vs placebo administration, in response to erotic and facialattraction stimuli.Results: Of the 40 participants who were randomized, 32 women completed both kisspeptin andplacebo visits, and the mean (SEM) age was 29.2 (1.2) years. Kisspeptin administration resulted inmodulations in sexual and facial attraction brain processing (all P<.05). Furthermore, positivecorrelations were observed between kisspeptin-enhanced hippocampal activity in response to eroticvideos, and baseline distress relating to sexual function (P<.01). In additio
AU  - Thurston,L
AU  - Hunjan,T
AU  - Ertl,N
AU  - Wall,M
AU  - Mills,E
AU  - Suladze,S
AU  - Patel,B
AU  - Alexander,E
AU  - Muzi,B
AU  - Bassett,P
AU  - Rabiner,E
AU  - Bech,P
AU  - Goldmeier,D
AU  - Abbara,A
AU  - Comninos,A
AU  - Dhillo,W
DO  - 10.1001/jamanetworkopen.2022.36131
EP  - 14
PY  - 2022///
SN  - 2574-3805
SP  - 1
TI  - Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial
T2  - Jama Network Open
UR  - http://dx.doi.org/10.1001/jamanetworkopen.2022.36131
UR  - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797718
UR  - http://hdl.handle.net/10044/1/99419
VL  - 5
ER  -
Download